Holen Sie sich die Stockscreener-App
2.60
6.56%
0.16
Handel nachbörslich:
2.62
0.02
+0.77%
Schlusskurs vom Vortag:
$2.44
Offen:
$2.47
24-Stunden-Volumen:
1.91M
Relative Volume:
1.32
Marktkapitalisierung:
$285.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-134.24M
KGV:
-1.4689
EPS:
-1.77
Netto-Cashflow:
$-121.34M
1W Leistung:
+10.64%
1M Leistung:
+0.78%
6M Leistung:
-13.62%
1J Leistung:
-54.27%
1-Tages-Spanne:
$2.45
$2.71
1-Wochen-Bereich:
$2.305
$2.71
52-Wochen-Spanne:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650)-822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Vergleichen Sie ANNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.60 | 257.83M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Can Annexon Inc. lead its sector in growthMarket Risk Summary & Weekly Top Gainers Trade List - 선데이타임즈
Is Annexon Inc. stock risky to hold nowCEO Change & Long Hold Capital Preservation Tips - newsyoung.net
Applying sector rotation models to Annexon Inc.Oversold Opportunity Scanner with RSI Data - Newser
Price momentum metrics for Annexon Inc. explainedTrade Flow Monitor with Volume Tracker - Newser
How Interest Rate Changes Impact Annexon Inc. Stock PerformancePredictive Screener for Daily Trade Watch - Newser
What makes Annexon Inc. stock price move sharplyChart Pattern Strategy with ROI Focus - Newser
Will a bounce in Annexon Inc. offer an exitSteady Return Plan Based on Data Analysis - Newser
Is Annexon Inc. stock trending bullishPredictable Big Profit Stocks - kangso.co.kr
How Annexon Inc. stock performs during market volatilityDownside Control Plan With Support Analysis - Newser
Annexon Inc. Building a Base Near SupportWeekly Watchlist of High Movers Released - beatles.ru
Trend analysis for Annexon Inc. this weekDay Trading Plan with Entry Risk Management - Newser
How to forecast Annexon Inc. trends using time seriesSafe Entry Screening with Data Backed Analysis - Newser
Combining price and volume data for Annexon Inc.Free ROI Driven Equity Selection With Safety - Newser
Momentum Screeners Rank Annexon Inc. in Top 5 TodaySwing Trading Entry Signals Suggest Opportunity Zone - metal.it
What is Annexon Inc. s 5 year growth outlookElite Portfolio Components - mustnews.co.kr
Will Annexon Inc. stock go up soonIntraday Price Forecast Using Volume Models - Newser
Annexon, Inc. Announces vonaprument's Selection for EMA's PDC Pilot Program, Paving the Way for Potential Dry AMD Treatment Approval - Quiver Quantitative
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy - The Manila Times
Breakthrough Eye Drug Among 20 Selected for EMA Fast Track: Could Be First Dry AMD Treatment in Europe - Stock Titan
What makes Annexon Inc. stock attractive to long term investorsHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
What is the dividend policy of Annexon Inc. stockDiscover the fastest growing stocks today - Jammu Links News
Why is Annexon Inc. stock attracting strong analyst attentionInvest smarter with expert stock picks - Jammu Links News
Should I hold or sell Annexon Inc. stock in 2025Identify undervalued stocks ready to soar - Jammu Links News
Does Annexon Inc. stock perform well during market downturnsOver 200% growth - Jammu Links News
Is Annexon Inc. a growth stock or a value stockCapitalize on momentum-driven investment opportunities - Jammu Links News
What is Annexon Inc. company’s growth strategyAccelerated profit realization - Jammu Links News
When is Annexon Inc. stock expected to show significant growthExtraordinary earning power - Jammu Links News
What markets is CYCC expanding into Is Annexon Inc. stock a good long term investment option - Jammu Links News
Annexon Inc. Stock Analysis and ForecastSuperior capital gains - Jammu Links News
What are analysts’ price targets for Annexon Inc. in the next 12 monthsBreakthrough wealth creation - Jammu Links News
Is Annexon Inc. a Top Dividend Stock to Watch in 2025Short-Term Profit Alert With Entry Forecast - Newser
Signal strength of Annexon Inc. stock in tech scannersPortfolio Review Summary with Five-Year Outlook - Newser
Carson William H. buys Annexon (ANNX) shares worth $9,999 By Investing.com - Investing.com Australia
Carson William H. buys Annexon (ANNX) shares worth $9,999 - Investing.com
Leading vs lagging indicators on Annexon Inc. performanceProven Trading System with Consistent Gains - Newser
Momentum divergence signals in Annexon Inc. chartFree High Win Rate Trading Opportunities - Newser
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Annexon (NASDAQ:ANNX) Trading 8.8% Higher – Still a Buy? - Defense World
Detecting price anomalies in Annexon Inc. with AIMachine Learning Stock Price Forecast Tool - Newser
Why did ANNX's operating profit drop sharply in Q4 2024? - AInvest
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):